Clay Siegall is among the science experts who are greatly appreciated for making tremendous contributions towards cancer treatment. He is a specialist in genetics and biotechnology and been hired by the government and various private institutions. Siegall has spent the last three decades working as a researcher, and his work has bettered he pharmaceuticals industry. He joined efforts with various biotechnology experts to establish Seattle Genetics in 1998. The primary focus of the enterprise has been to develop safe cancer treatments that do not have harsh side effects on the patients. Chemotherapies are currently used in curing cancer, but they lead to hair loss and many other problems.
Seattle Genetics has now become a research hub that has employed many biotechnology experts to developed cancer cures. It has secured FDA licenses for various therapies that it has created. The company is recognized for being the pioneer in the development of antibody drug conjugates. This technology is used in cancer treatment and is safer compared to chemotherapies. Seattle Genetics has made a lot of money from ADCs through the internal production of drugs, licensing corporations to use the technology in making drugs, and partnering with companies to manufacture drugs externally. The firms that it is currently working with include Takeda, Bayer, and Genentech Pharmaceuticals.
Siegall has been an excellent administrator for the past two decades that he has served Seattle Genetics. He is the firm’s CEO and the chairman of its board. He has guided it in developing different targeted cancer therapies and is still working to improve them. Clay trusts the expertise of the company’s employees since they have assisted it in developing top-notch cures and have been approved by the FDA.
The biotechnology expert has gained a lot of experience in the past three decades that he has been a researcher. He currently acts as a board member of companies such as Mirna Therapeutics, Ultragenyx, and BioPharmaceuticals. Clay has made significant accomplishments in his career. This includes developing 15 patented technologies and writing more than 70 research articles. He is a holder of a Ph.D. in genetics and a bachelor’s degree in biotechnology.